ArticleCancer cell international2026
PSMD8 promotes breast cancer progression and attenuates paclitaxel sensitivity by stabilizing KIF10.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBreast cancer (BC) patients have been threatened by distant metastasis and variations in treatment response for a long time. The mechanism urgently remains to be explored.
methodsBioinformatics analysis were performed to indicate the expression and function of related markers, and verified in BC tissues as well as adjacent tissues. Functional assays employed in vitro and in vivo with PSMD8 knockdown or overexpression. Mechanistic studies evaluated the ubiquitination degradation process via co-immunoprecipitation and rescue experiments.
resultsIn the present study, PSMD8 was abnormally upregulated in BC tissues compared with adjacent tissues and was related to poor prognosis in BC patients. The knockdown of PSMD8 attenuated the biological effect and EMT progression in vitro and in vivo and augmented the sensitivity of BC cells to paclitaxel, whereas PSMD8 overexpression showed the opposite effects. Mechanistic analysis indicated that PSMD8 stabilized KIF10, and we observed its tumor-promoting effect in BC tumor cells. Moreover, KIF10 knockdown significantly antagonized the facilitating effect of PSMD8 on the EMT program and response to paclitaxel treatment. Finally, the PSMD8/KIF10 axis activated the ERK pathway. Inhibiting the ERK pathway in PSMD8-overexpressing cell lines partially blocked EMT progression and altered the cellular response to paclitaxel.
conclusionIn conclusion, our results demonstrated that the PSMD8/KIF10 axis promoted BC development and modulated paclitaxel sensitivity via the ERK pathway. Our findings provide a theoretical basis for targeting PSMD8 to BC cells as a novel target for the treatment of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.